192 related articles for article (PubMed ID: 16180027)
1. Does testing for prostate-specific antigen contribute to declining prostate cancer mortality? Estimating the broader economic influences on aggregate prostate cancer mortality rates.
Di Matteo L; Di Matteo R
Eur J Health Econ; 2005 Dec; 6(4):298-308. PubMed ID: 16180027
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
3. PSA screening and prostate cancer mortality.
Perron L; Moore L; Bairati I; Bernard PM; Meyer F
CMAJ; 2002 Mar; 166(5):586-91. PubMed ID: 11898936
[TBL] [Abstract][Full Text] [Related]
4. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
[TBL] [Abstract][Full Text] [Related]
5. Impact of screening on prostate cancer rates and trends.
Mettlin C
Microsc Res Tech; 2000 Dec; 51(5):415-8. PubMed ID: 11074610
[TBL] [Abstract][Full Text] [Related]
6. PSA testing in Austria: induced morbidity and saved mortality.
Vutuc C; Waldhoer T; Lunglmayr G; Hoeltl W; Haidinger G
Eur J Cancer Prev; 2009 Sep; 18(5):377-80. PubMed ID: 19512934
[TBL] [Abstract][Full Text] [Related]
7. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
8. Rural residence and prostate cancer screening with prostate-specific antigen.
Stamatiou K; Skolarikos A
Rural Remote Health; 2009; 9(2):1227. PubMed ID: 19594290
[TBL] [Abstract][Full Text] [Related]
9. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
Merrill RM; Stephenson RA
J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
[TBL] [Abstract][Full Text] [Related]
10. Quebec prostate cancer mortality dropped in 1996.
Meyer F; Moore L; Bairati I; Fradet Y
Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
[TBL] [Abstract][Full Text] [Related]
11. The increased rate of prostate specific antigen testing has not affected prostate cancer presentation in an inner city population in the UK.
Mokete M; Shackley DC; Betts CD; O'Flynn KJ; Clarke NW
BJU Int; 2006 Feb; 97(2):266-9. PubMed ID: 16430626
[TBL] [Abstract][Full Text] [Related]
12. Physician clinical experience and inappropriate prostate specific antigen screening: evidence from an Asian country.
Kuo NW; Lin HC; Lee HC
J Urol; 2008 Nov; 180(5):1954-8; discussion 1958. PubMed ID: 18801533
[TBL] [Abstract][Full Text] [Related]
13. Changes in case mix and treatment patterns in prostate cancer in Saskatchewan during the prostate specific antigen testing era.
Tonita JM; Skarsgard D; Muhajarine N
Cancer Causes Control; 2009 Mar; 20(2):201-9. PubMed ID: 18825504
[TBL] [Abstract][Full Text] [Related]
14. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
15. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
Kvåle R; Auvinen A; Adami HO; Klint A; Hernes E; Møller B; Pukkala E; Storm HH; Tryggvadottir L; Tretli S; Wahlqvist R; Weiderpass E; Bray F
J Natl Cancer Inst; 2007 Dec; 99(24):1881-7. PubMed ID: 18073376
[TBL] [Abstract][Full Text] [Related]
16. An ecologic study of prostate-specific antigen screening and prostate cancer mortality in nine geographic areas of the United States.
Shaw PA; Etzioni R; Zeliadt SB; Mariotto A; Karnofski K; Penson DF; Weiss NS; Feuer EJ
Am J Epidemiol; 2004 Dec; 160(11):1059-69. PubMed ID: 15561985
[TBL] [Abstract][Full Text] [Related]
17. Changes in baseline PSA levels in Japanese men from 1988 to 2003.
Ohi M; Ito K; Yamamoto T; Miyakubo M; Takechi H; Kubota Y; Suzuki K
Urology; 2008 Jul; 72(1):95-8. PubMed ID: 18455775
[TBL] [Abstract][Full Text] [Related]
18. Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing.
Oberaigner W; Horninger W; Klocker H; Schönitzer D; Stühlinger W; Bartsch G
Am J Epidemiol; 2006 Aug; 164(4):376-84. PubMed ID: 16829552
[TBL] [Abstract][Full Text] [Related]
19. [Epidemiology of prostate cancer in the Limousin area].
Druet-Cabanac M; Colombeau P; Preux PM; Paulhac P; Vergnenegre A; Dumas JP
Prog Urol; 2002 Apr; 12(2):226-31. PubMed ID: 12108336
[TBL] [Abstract][Full Text] [Related]
20. Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach.
Etzioni R; Gulati R; Falcon S; Penson DF
Med Decis Making; 2008; 28(3):323-31. PubMed ID: 18319508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
